Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nanjing Medical To Build Health Care Industrial Park

This article was originally published in PharmAsia News

Executive Summary

Nanjing Medical Company has signed a 20-year real estate and land lease with Nanjing Compressor Co., Ltd. According to the contract, Nanjing Compressor will lease its number one production zone including all buildings, auxiliary equipment, facilities, fittings and land to Nanjing Medical at a total of 229.19 million yuan for the next 20 years. Nanjing Medical is to put in 5.5 million yuan for 55 percent equity of a new management company, which will be set up to oversee construction of the industrial park. With its focus on integrating logistics resources, Nanjing Medical is looking for investors to develop the municipal park into a center for high-end preventive medicine, health care and rehabilitation, business, product R&D and modern logistics. (Click here for more - Chinese Language)

You may also be interested in...

European Commission Decides CBD Is Not A Drug Opening Up Novel Food Pathway

The European Commission has unexpectedly concluded that CBD should not be considered as drug opening up the path to regulated EU market for the cannabinoid as a novel food.

Who’s Hired? Apotex Names New US President & CEO

As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles. 

UN Rejects Proposal To Exempt CBD From International Narcotics Controls

A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts